Introduction
============

Hepatocellular carcinoma (HCC) accounts for 95% of primary liver cancer[@b1-dddt-11-851] and is the second most common cause of cancer-associated death worldwide.[@b2-dddt-11-851] Liver resection and liver transplantation are the only curative treatments for HCC. The majority of patients, however, are not eligible for either resection or transplantation because of advanced tumor stage, underlying liver dysfunction, and lack of donor organs. Additionally, postoperative recurrence is frequent and can be as high as 25% per year, leading to death of \~80% of patients within 12 months of diagnosis.[@b3-dddt-11-851],[@b4-dddt-11-851] Other therapeutic options, such as percutaneous chemical, thermal, or radiofrequency ablation (RFA); transarterial chemoembolization (TACE); chemotherapy; and targeted therapy, also have limited efficacy.[@b5-dddt-11-851] Therefore, finding effective methods to increase efficacy of treatment and reduce recurrence rate is of utmost importance in the therapy of HCC.

Immunotherapy has been considered as a potential treatment option for HCC for a number of years.[@b6-dddt-11-851],[@b7-dddt-11-851] Several approaches to immunotherapy for HCC have shown promise in early clinical trials. These treatments can be divided into four main categories: immune checkpoint inhibitors, monoclonal antibodies, adoptive cell transfer, and oncolytic virus therapy.[@b7-dddt-11-851] Adoptive cytokine-induced killer (CIK) cell transfer is one of the promising avenues of immunotherapy for HCC. CIK cells are non-major histocompatibility complex--restricted cells that exhibit strong cytolytic activities against susceptible tumors[@b8-dddt-11-851] and express both T- and natural killer (NK) cell markers, CD3 and CD56, respectively.[@b9-dddt-11-851] CIK cells can be generated from human peripheral blood mononuclear cells through induction with interferon-γ, anti-CD3 antibody, and interleukin-2.[@b8-dddt-11-851] There are a number of advantages of CIK cells compared with other immune cells. CIK cells have a higher proliferation rate and can be obtained directly from cancer patients.[@b10-dddt-11-851] Additionally, CIK cells have strong cytolytic activities and recognize a number of tumors, including those that are resistant to lymphokine-activated killer cells or NK cells.[@b11-dddt-11-851] Furthermore, CIK cells were not shown to cause graft-versus-host disease.[@b7-dddt-11-851],[@b8-dddt-11-851] Therefore, CIK cells present a promising immunotherapy approach that could be used for HCC patients.[@b12-dddt-11-851]

And indeed, a number of recent clinical trials have demonstrated that adoptive infusion of CIK cells was associated with a substantial antitumor effect in HCC patients.[@b13-dddt-11-851]--[@b19-dddt-11-851] CIK cell transfer was shown to decrease the rate of relapse after TACE and RFA therapy and increase disease-free survival and overall survival for HCC patients after liver resection or TACE.[@b13-dddt-11-851]--[@b19-dddt-11-851]

However, despite the increasing evidence pointing to CIK cells as a viable option for HCC treatment, more translational research and clinical trials are needed to provide convincing evidence regarding the efficacy of CIK cell immunotherapy. The aim of the present meta-analysis was to assess the efficacy and safety of CIK cell-based immunotherapy as an adjuvant therapy for HCC.

Materials and methods
=====================

Search strategy
---------------

We followed the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) guidance for systematic reviews of observational and diagnostic studies[@b20-dddt-11-851] and searched the published literature using the Medline, Cochrane, EMBASE, and Google Scholar databases through November 6, 2015, with various combinations of the following keywords: cytokine-induced killer, CIK, hepatocellular carcinoma, HCC, liver neoplasm, and immunotherapy. The specific search terms were the following: (((hepatocellular carcinoma) OR HCC) OR liver neoplasm) AND ((cytokine-induced killer cell) OR CIK), with the following filters: Humans, Abstract available, Clinical study, Clinical trial, Meta-analysis, Review, and Systematic review. We manually searched references in relevant publications to identify additional eligible trials. The inclusion criteria were as follows: 1) randomized controlled trials (RCTs) and prospective or retrospective studies; 2) patients who were initially diagnosed with HCC and allocated to either an adoptive immunotherapy group or a control group; and 3) quantitative outcomes (overall survival, progression-free survival, and disease-free survival). The exclusion criteria were as follows: 1) format of cohort study, letter, comment, editorial, case report, proceeding, or personal communication; 2) patients without a diagnosis of HCC; 3) study designed for adoptive immunotherapy with other cell types (eg, NK cells, dendritic cells); and 4) no quantitative outcomes.

Study selection and data extraction
-----------------------------------

Data were extracted independently by two reviewers. A third reviewer was consulted in case of disagreements. We extracted data on study population (number, age, and gender of patients in each group), study design, length of follow-up time, Child--Pugh Class, cancer stage, viral hepatitis profile, and data for overall survival (OS), progression-free survival (PFS), and disease-free survival (DFS).

Quality assessment
------------------

We assessed study quality using the Cochrane Risk of Bias Tool.[@b21-dddt-11-851] The quality assessment was performed by two independent reviewers; the third reviewer was consulted if no consensus could be reached. The quality assessment of included studies is presented in [Figure 1](#f1-dddt-11-851){ref-type="fig"}.

Statistical analysis
--------------------

The outcomes of interest were OS, PFS, and DFS. Hazard ratios (HR) and 95% confidence intervals (95% CI) reported by individual studies were used as the outcome measures. If not provided in individual studies, the HR and 95% CI were calculated from summary statistics of time-to-event analyses with the methods proposed by Tierney et al.[@b22-dddt-11-851]

Heterogeneity among the studies was assessed by the Cochran *Q* and the *I*^2^ statistic. The *Q* statistic was defined as the weighted sum of the squared deviations of the estimates of all studies; *P*\<0.10 was considered statistically significant for heterogeneity. For the *I*^2^ statistic, which indicated the percentage of the observed between-study variability due to heterogeneity, the ranges used were the following: no heterogeneity (*I*^2^=0%--25%), moderate heterogeneity (*I*^2^=25%--50%), large heterogeneity (*I*^2^=50%--75%), and extreme heterogeneity (*I*^2^=75%--100%).

The random-effect model (DerSimonian--Laird method) was used to generate pooled estimates across studies for each outcome. A two-sided *P*-value \<0.05 was considered statistically significant. All analyses that were performed were stratified by study design (ie, randomized and nonrandomized trials). To assess whether a single study impacts the pooled results, a sensitivity analysis was performed using the leave-one-out approach. All statistical analyses were performed with the statistical software Comprehensive Meta-Analysis, version 2.0 (Biostat, Englewood, NJ, USA).

Results
=======

Basic characteristics of included studies
-----------------------------------------

After considering the inclusion and exclusion criteria, eight randomized trials,[@b13-dddt-11-851],[@b14-dddt-11-851],[@b18-dddt-11-851],[@b23-dddt-11-851]--[@b27-dddt-11-851] six prospective studies,[@b15-dddt-11-851],[@b28-dddt-11-851]--[@b33-dddt-11-851] and three retrospective studies[@b16-dddt-11-851],[@b17-dddt-11-851],[@b32-dddt-11-851] were eligible for this review ([Figure 2](#f2-dddt-11-851){ref-type="fig"}). The eligible studies analyzed a total of 1,979 patients with HCC, 1,029 of whom underwent adjuvant immunotherapy with CIK cells. The number of patients ranged from 38 to 410 per study. The patients' age ranged from 43 to 56 years. The proportion of male patients ranged from 52.4% to 97.8%. Information regarding patient demographics, liver function, stage of HCC, hepatitis infection, and treatment regimens is summarized in [Table 1](#t1-dddt-11-851){ref-type="table"}. The treatment used by the majority of studies was TACE, either alone (six studies) or in combination with RFA (five studies), percutaneous ethanol injection (one study), or surgery (one study). Surgery was the second most common treatment, used alone (two studies) or with RFA and percutaneous ethanol injection (one study). For all studies, patients who received CIK cell immunotherapy also received the same treatment as the control group.

Outcome measures
----------------

A summary of the data for OS, PFS, and DFS is shown in [Table 2](#t2-dddt-11-851){ref-type="table"}. A total of 7 RCTs[@b14-dddt-11-851],[@b18-dddt-11-851],[@b23-dddt-11-851]--[@b27-dddt-11-851] and 9 non-RCTs[@b14-dddt-11-851]--[@b17-dddt-11-851],[@b28-dddt-11-851]--[@b33-dddt-11-851] reported the HR for overall survival. There was significant heterogeneity among the studies (RCTs: *I* [@b2-dddt-11-851]=50.4%, *P*=0.060; non-RCTs: *I* [@b2-dddt-11-851]=43.3%, *P*=0.079; overall: *I* [@b2-dddt-11-851]=47.2%, *P*=0.019). The overall analysis revealed that patients in the CIK cell-treatment group had a higher survival rate (pooled HR =0.594, 95% CI =0.501--0.703, *P*\<0.001). The results were similar for both RCTs (pooled HR =0.644, 95% CI =0.506--0.820, *P*\<0.001) and non-RCTs (pooled HR =0.548, 95% CI =0.432--0.695, *P*\<0.001) ([Figure 3A](#f3-dddt-11-851){ref-type="fig"}).

One RCT[@b23-dddt-11-851] and 4 non-RCTs[@b15-dddt-11-851],[@b16-dddt-11-851],[@b28-dddt-11-851],[@b33-dddt-11-851] analyzed the HR for PFS and were included in the meta-analysis. There was no evidence of heterogeneity across individual non-RCT studies (*I* [@b2-dddt-11-851]=0%, *P*=0.642). Analysis of RCTs revealed that there was no significant difference between the PFS rate in patients with or without CIK treatment (HR =0.700, 95% CI =0.452--1.084, *P*=0.110). The overall analysis of the non-RCTs indicated a higher rate of PFS in patients treated with CIK cells (pooled HR =0.613, 95% CI =0.510--0.738, *P*\<0.001). The comparison between the pooled results from RCTs and that of non-RCTs ([Figure 3B](#f3-dddt-11-851){ref-type="fig"}) regarding the PFS rate did not reach statistical significance.

One non-RCT[@b30-dddt-11-851] and 4 RCTs[@b13-dddt-11-851],[@b14-dddt-11-851],[@b18-dddt-11-851],[@b24-dddt-11-851] reported the HR for disease-free survival. There was no evidence of heterogeneity across the four RCTs that were included in the meta-analysis of the disease-free survival rate (*I* [@b2-dddt-11-851]=0%, *P*=0.781). The overall analysis of RCTs revealed that patients treated with CIK cells had lower rates of relapse or recurrence (pooled HR =0.635, 95% CI =0.514--0.784, *P*\<0.001). Similar results were also found when non-RCT and RCTs were pooled (pooled HR =0.623, 95% CI =0.516--0.752, *P*\<0.001) ([Figure 3C](#f3-dddt-11-851){ref-type="fig"}).

Sensitivity analysis and publication bias
-----------------------------------------

Sensitivity analyses were performed using the leave-one-out approach ([Figure 4](#f4-dddt-11-851){ref-type="fig"}). For all outcomes, the direction and magnitude of the combined estimates did not vary markedly with the removal of one of the studies, indicating that the data were not overly influenced by each study. Publication bias was not assessed due to small sample size.[@b34-dddt-11-851]

Quality assessment
------------------

We assessed the study quality of the prospective studies included in this meta-analysis using the Cochrane Risk of Bias Tool ([Figure 1](#f1-dddt-11-851){ref-type="fig"}). There were eight studies with potential selection bias for random sequence generation, and two studies had potential for allocation concealment bias. None of the included studies was double-blinded, and only two studies were blinded for outcome assessment ([Figure 1A](#f1-dddt-11-851){ref-type="fig"}). There were 11 studies with low risk in attrition bias and 15 studies with low risk of reporting bias. Overall, the quality of included studies was limited due to the study design and difficulty with blinding ([Figure 1B](#f1-dddt-11-851){ref-type="fig"}). The described issues were partially related to the procedure used to administer the CIK cell therapy as well as the ethics behind patient allocation to treatment groups.

Discussion
==========

The effectiveness of the current therapies for advanced HCC is limited, and the incidence of treatment-related adverse reactions is high, particularly in elderly patients with underlying liver conditions.[@b4-dddt-11-851] Therefore, new treatment modalities, capable of prolonging survival in patients with advanced HCC while minimizing the risk of adverse reactions, are urgently needed. Immunotherapy has a potential to offer systemic, nontoxic, and durable antitumor effects, and therefore is highly attractive as a treatment option for HCC. HCC tumor cells can be targeted by various immune effector mechanisms,[@b7-dddt-11-851] including by using CIK cells as effector cells. CIK cells belong to the T-cell population, display a T-cell-and NK cell-like phenotype, and are characterized by a non-major histocompatibility complex--restricted tumor killing activity.[@b7-dddt-11-851] Recently, a number of clinical trials have been undertaken to evaluate CIK cell-based immunotherapy in the treatment of HCC. To summarize and evaluate the most recent findings regarding the efficacy and safety of CIK cell immunotherapy as an adjuvant treatment for HCC, we performed the current meta-analysis.

We found that patients who underwent CIK cell-based immunotherapy had a higher rate of overall survival compared to patients who did not receive CIK cell-based therapy. The observed results were similar in both RCTs and non-RCTs. Additionally, patients who underwent CIK cell-based immunotherapy had lower rates of tumor recurrence. While we did not observe a statistically significant difference between the patients in the intervention and control groups regarding the PFS rate, the observed trend was in favor of CIK cell-based immunotherapy.

The studies included in this meta-analysis did not report adverse and unexpected side effects of the treatment. Several studies[@b16-dddt-11-851],[@b18-dddt-11-851],[@b26-dddt-11-851],[@b33-dddt-11-851] reported constitutional symptoms, such as fever and chills, in some patients who received therapy with CIK cells. Yu et al,[@b23-dddt-11-851] reported nausea in 4 patients in the CIK cell group and in 5 patients in the non-CIK cell group. One patient was allergic to CIK cells in the 2014 study by Guo et al.[@b33-dddt-11-851]

Our meta-analysis is the most current, with rather broad inclusion parameters. We included RCTs and non-RCTs, as well as studies published in English and Chinese. Overall, our results are in agreement with previous studies. Ma et al[@b35-dddt-11-851] analyzed 13 articles reporting phase II and III clinical trials of CIK cell-based therapy in the treatment of HCC. This meta-analysis revealed a significant advantage of CIK cell-combined therapy in prolonging the overall survival of patients. Pooled analysis showed that treatment with CIK cells was associated with significantly improved 1-year survival (odds ratio \[OR\] =0.25, 95% CI =0.12--0.52, *P*\<0.001) and 2-year survival (OR =0.17, 95% CI =0.07--0.43, *P*\<0.001), but not half-year survival (77% in the CIK cell group versus 67% in the non-CIK cell group; OR =0.43, 95% CI =0.05--3.94, *P*=0.45). CIK cell-based treatment was also associated with a significantly prolonged half-year and 1-year PFS (OR =0.29, 95% CI =0.16--0.52, *P*\<0.001; OR =0.35, 95% CI =0.22--0.53, *P*\<0.001, respectively).[@b35-dddt-11-851] We did not observe a significant improvement of PFS in the CIK cell treatment group in our meta-analysis, possibly due to differences in the study designs of the included studies, eg, number of RCTs versus non-RCTs. Recently, another meta-analysis assessed the efficacy of CIK cell therapy after TACE or TACE plus RFA and showed that CIK cell therapy combined with TACE plus RFA treatment was associated with a higher 1-year recurrence-free survival rate and 1- and 2-year OS rates.[@b36-dddt-11-851] While subgroup analysis based on the prior treatment was beyond the scope of our review, it should be further investigated in future studies. Furthermore, subgroup analysis based on other parameters, such as stage of cancer and exact therapeutic regimen, would be beneficial in providing a better understanding of the effectiveness of immunotherapy and determining optimal therapeutic approaches for treatment of HCC.

The conclusions of this meta-analysis are subject to several limitations. Despite inclusion of non-English publications, the number of analyzed studies is limited, potentially leading to random errors. Another major drawback of the study is the moderate to large heterogeneity among the studies included for analysis of overall survival.

Conclusion
==========

Our results highlight that adjuvant CIK cell-based immunotherapy is a promising therapeutic modality that can improve OS and reduce recurrence in patients with HCC. Future studies with subgroup analyses including etiologic factors, liver function, previous treatments, and disease stage should help to identify groups of HCC patients who would benefit the most from CIK cell-based immunotherapy.
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###### 

Summary of basic characteristics of studies selected for meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study (year published)                Study design    Treatment                      Number of patients   Mean age, years                                 Male gender   Follow-up time, months        Child--Pugh class, number (%)   Cancer stage, no (%)   Type of viral hepatitis, number (%)
  ------------------------------------- --------------- ------------------------------ -------------------- ----------------------------------------------- ------------- ----------------------------- ------------------------------- ---------------------- -------------------------------------
  Lee et al,[@b18-dddt-11-851] 2015     RCT             Surgery/RFA/PEI + CIK          114                  55.4                                            83.3%         NR                            NR                              AJCC\                  HBV only: 96 (84.2%)\
                                                                                                                                                                                                                                        I: 98 (86.0%)\         HCV only: 9 (7.9%)\
                                                                                                                                                                                                                                        II: 16 (14.0%)         HBV + HCV: 2 (1.8%)\
                                                                                                                                                                                                                                                               Others: 7 (6.1%)

                                                        Surgery/RFA/PEI                112                  56.4                                            81.3%                                                                       AJCC\                  HBV only: 90 (80.4%)\
                                                                                                                                                                                                                                        I: 94 (83.9%)\         HCV only: 10 (8.9%)\
                                                                                                                                                                                                                                        II: 18 (16.1%)         HBV + HCV: 2 (1.8%)\
                                                                                                                                                                                                                                                               Others: 10 (8.9%)

  Guo et al,[@b33-dddt-11-851] 2014     Retrospective   TACE + CIK                     30                   ≤60: 43.3%\                                     90.0%         Range: 2--43                  A: 24 (80%)\                    BCLC\                  HBsAg+: 28 (93.3%)
                                                                                                            \>60: 56.7%                                                                                 B: 6 (20%)                      A: 5 (16.7%)\          
                                                                                                                                                                                                                                        B: 15 (50%)\           
                                                                                                                                                                                                                                        C: 10 (33.3%)          

                                                        TACE only                      38                   ≤60: 34.2%\                                     89.5%                                       A: 31 (81.6%)\                  BCLC\                  HBsAg+: 36 (94.7%)
                                                                                                            \>60: 65.8%                                                                                 B: 7 (18.4%)                    A: 5 (13.1%)\          
                                                                                                                                                                                                                                        B: 21 (55.3%)\         
                                                                                                                                                                                                                                        C: 12 (31.6%)          

  Yu et al[@b23-dddt-11-851] 2014       RCT             Standard treatment + CIK       66                   \<60: 56.1%\                                    87.9%         Median: 18.6                  A: 62\                          BCLC\                  Hepatitis B: 35
                                                                                                            ≥60: 43.9%                                                                                  B: 4                            A: 8\                  
                                                                                                                                                                                                                                        B: 31\                 
                                                                                                                                                                                                                                        C: 27                  

                                                        Standard treatment             66                   \<60: 65.2%\                                    87.9%                                       A: 62\                          BCLC\                  Hepatitis B: 37
                                                                                                            ≥60: 34.8%                                                                                  B: 4                            A: 8\                  
                                                                                                                                                                                                                                        B: 31\                 
                                                                                                                                                                                                                                        C: 27                  

  Pan et al,[@b17-dddt-11-851] 2013     Retrospective   Surgery alone                  206                  50.03                                           86.9%         Median: 60                    NR                              Pathology\             HBsAg+: 176\
                                                                                                                                                                                                                                        I: 17\                 HBeAg+: 182
                                                                                                                                                                                                                                        II: 92\                
                                                                                                                                                                                                                                        III: 97                

                                                        Surgery + CIK                  204                  49.16                                           87.3%                                                                       Pathology\             HBsAg+: 47\
                                                                                                                                                                                                                                        I: 18\                 HBeAg+: 43
                                                                                                                                                                                                                                        II: 102\               
                                                                                                                                                                                                                                        III: 84                

  Huang et al,[@b16-dddt-11-851] 2013   Retrospective   TACE + RFA + CIK               85                   50[a](#tfn1-dddt-11-851){ref-type="table-fn"}   90.6%         Median (range): 78 (5--173)   A: 76\                          BCLC\                  HBV: 66
                                                                                                                                                                                                        B: 9                            A: 36\                 
                                                                                                                                                                                                                                        B: 29\                 
                                                                                                                                                                                                                                        C: 20                  

                                                        TACE + RFA                     89                   53[a](#tfn1-dddt-11-851){ref-type="table-fn"}   88.8%                                       A: 74\                          BCLC\                  HBV: 69
                                                                                                                                                                                                        B: 15                           A: 37\                 
                                                                                                                                                                                                                                        B: 34\                 
                                                                                                                                                                                                                                        C: 18                  

  Tong et al,[@b28-dddt-11-851] 2013    Prospective     TACE + CIK\                    20\                  56                                              NR            NR                            NR                              NR                     NR
                                                        TACE only                      18                                                                                                                                                                      

  Deng et al,[@b24-dddt-11-851] 2013    RCT             TACE + RFA                     21                   ≥50: 81.0%\                                     52.4%         NR                            A: 19\                          NR                     HBsAg+: 20
                                                                                                            \<50: 19.0%                                                                                 B: 2                                                   

                                                        TACE + RFA + CIK               20                   ≥50: 65.0%\                                     90.0%                                       A: 18\                                                 HBsAg+: 17
                                                                                                            \<50: 35.0%                                                                                 B: 2                                                   

  He et al,[@b25-dddt-11-851] 2012      RCT             TACE only                      58                   52.1                                            86.2%         Mean: 40                      A: 49\                          NR                     NR
                                                                                                                                                                                                        B: 9                                                   

                                                        TACE + CIK                     60                   56.3                                            93.3%                                       A: 54\                                                 
                                                                                                                                                                                                        B: 6                                                   

  Wang et al,[@b30-dddt-11-851] 2012    Prospective     TACE + RFA + CIK               38                   53                                              89.5%         Mean: 44                      A: 27\                          NR                     HBV: 31
                                                                                                                                                                                                        B: 11                                                  

                                                        TACE + RFA                     38                   55                                              86.8%                                       A: 25\                                                 HBV: 32
                                                                                                                                                                                                        B: 13                                                  

  Hao et al,[@b15-dddt-11-851] 2010     Prospective     TACE + CIK                     72                   53[a](#tfn1-dddt-11-851){ref-type="table-fn"}   90.3%         NR                            A: 65\                          BCLC\                  HBsAg+: 68
                                                                                                                                                                                                        B: 7                            A: 7\                  
                                                                                                                                                                                                                                        B: 6\                  
                                                                                                                                                                                                                                        C: 59                  

                                                        TACE only                      74                   51[a](#tfn1-dddt-11-851){ref-type="table-fn"}   86.5%                                       A: 66 B: 8                      BCLC\                  HBsAg+: 68
                                                                                                                                                                                                                                        A: 5\                  
                                                                                                                                                                                                                                        B: 4\                  
                                                                                                                                                                                                                                        C: 65                  

  Dong et al,[@b14-dddt-11-851] 2009    RCT             Surgery + CIK-I                41                   ≥50: 65.9%\                                     75.6%         NR                            A: 34\                          NR                     HBsAg+: 32
                                                                                                            \<50: 34.1%                                                                                 B: 7                                                   

                                                        Surgery + CIK-II               43                   ≥50: 60.5%\                                     74.4%                                       A: 34\                                                 HBsAg+: 33
                                                                                                            \<50: 39.5%                                                                                 B: 9                                                   

                                                        Surgery only                   43                   ≥50: 65.1%\                                     79.1%                                       A: 34\                                                 HBsAg+: 31
                                                                                                            \<50: 34.9%                                                                                 B: 9                                                   

  Yu et al,[@b32-dddt-11-851] 2009      Prospective     Surgery + TACE + CIK           25                   49                                              88.0%         Range: 3--34                  A: 24\                          Clinical\              NR
                                                                                                                                                                                                        B: 1                            I: 0\                  
                                                                                                                                                                                                                                        II: 8\                 
                                                                                                                                                                                                                                        III: 15\               
                                                                                                                                                                                                                                        IV: 2                  

                                                        Surgery + supportive therapy   25                   52                                              92.0%                                       A: 20\                          Clinical\              
                                                                                                                                                                                                        B: 5                            I: 1\                  
                                                                                                                                                                                                                                        II: 9\                 
                                                                                                                                                                                                                                        III: 14\               
                                                                                                                                                                                                                                        IV: 1                  

  Weng et al,[@b13-dddt-11-851] 2008    RCT             TACE + RFA + CIK               45                   43[a](#tfn1-dddt-11-851){ref-type="table-fn"}   68.9%         Max: 18                       A: 36 (80%)\                    NR                     NR
                                                                                                                                                                                                        B: 9 (20%)                                             

                                                        TACE + RFA                     40                   45[a](#tfn1-dddt-11-851){ref-type="table-fn"}   72.5%                                       A: 33 (82.5%)\                                         
                                                                                                                                                                                                        B: 7 (17.5%)                                           

  Huang et al,[@b26-dddt-11-851] 2007   RCT             TACE + RFA + CIK\              55\                  46.2\                                           67.3%\        NR                            NR                              NR                     NR
                                                        TACE + RFA                     30                   47.1                                            70.0%                                                                                              

  Shi et al,[@b31-dddt-11-851] 2007     Prospective     TACE + CIK                     38                   NR                                              NR            NR                            NR                              Okuda\                 NR
                                                                                                                                                                                                                                        I: 8\                  
                                                                                                                                                                                                                                        II: 13\                
                                                                                                                                                                                                                                        III: 7                 

                                                        TACE                           134                                                                                                                                              Okuda\                 
                                                                                                                                                                                                                                        I: 2\                  
                                                                                                                                                                                                                                        II: 106\               
                                                                                                                                                                                                                                        III: 26                

  Hao et al,[@b29-dddt-11-851] 2006     Prospective     TACE + CIK                     21                   50.90                                           81.0%         NR                            A: 15\                          Clinical\              HBV infection: 21
                                                                                                                                                                                                        B: 4\                           I: 2\                  
                                                                                                                                                                                                        C: 2                            II: 16\                
                                                                                                                                                                                                                                        III: 3                 

                                                        TACE only                      46                   49.83                                           97.8%                                       A: 34\                          Clinical\              HBV infection: 44
                                                                                                                                                                                                        B: 9\                           I: 4\                  
                                                                                                                                                                                                        C: 3                            II: 39\                
                                                                                                                                                                                                                                        III: 3                 

  Zhang et al,[@b27-dddt-11-851]\       RCT             TACE only\                     30\                  45.5                                            75.0%         NR                            NR                              NR                     NR
  2006                                                  TACE + CIK\                    16\                                                                                                                                                                     
                                                        TACE + PEI\                    62\                                                                                                                                                                     
                                                        TACE + PEI + CIK               36                                                                                                                                                                      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Data for age are presented as the median.

**Abbreviations:** AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; CIK, cytokine-induced killer cells; HBsAg, surface antigen of the hepatitis B virus; HBV, hepatitis B virus; HCV, hepatitis C virus; NR, not recorded; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization.

###### 

Summary of outcomes of included studies

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                 Number of patients   Mean age (yr)                                    Inclusion criteria                                                                                          Treatment                      OS (HR)                PFS (HR)               DFS (HR)
  ------------------------------------- -------------------- ------------------------------------------------ ----------------------------------------------------------------------------------------------------------- ------------------------------ ---------------------- ---------------------- ----------------------
  Lee et al,[@b18-dddt-11-851] 2015     114                  55.4                                             1\. Patients with HCC clinical stage I or II according to AJCC\                                             Surgery/RFA/PEI + CIK          0.21 (0.06--0.75)      NR                     (Adjusted) 0.66\
                                                                                                              2. Child--Pugh class A                                                                                                                                                                   (0.44--0.98)

                                        112                  56.4                                             3\. ECOG score 0 or 1\                                                                                      Surgery/RFA/PEI                                                              
                                                                                                              4. Age between 20 and 80 years                                                                                                                                                           

  Guo et al,[@b33-dddt-11-851] 2014     30                   ≤60: 43.3%\                                      1\. Age \>18 years\                                                                                         TACE + CIK                     0.75 (0.43--1.31)      0.46 (0.25--0.86)      NR
                                                             \>60: 56.7%                                      2. Child--Pugh A or B\                                                                                                                                                                   
                                                                                                              3. KPS ≥70\                                                                                                                                                                              
                                                                                                              4. Without ascites or distant metastatic disease                                                                                                                                         

                                        38                   ≤60: 34.2%\                                      5\. Life expectancy \>6 months\                                                                             TACE only                                                                    
                                                             \>60: 65.8%                                      6. Without severe infection or pregnancy                                                                                                                                                 

  Yu et al,[@b23-dddt-11-851] 2014      66                   \<60: 56.1%\                                     1\. Age between 18 and 80 years\                                                                            Standard treatment + CIK       0.62 (0.37--1.06)      0.7 (0.45--1.08)       NR
                                                             ≥60: 43.9%                                       2. Child--Pugh score A or B\                                                                                                                                                             
                                                                                                              3. BCLC stage A, B or C\                                                                                                                                                                 
                                                                                                              4. Life expectancy \>3 months                                                                                                                                                            

                                        66                   \<60: 65.2%\                                     5\. Without severe cardiovascular disease or pregnancy                                                      Standard treatment                                                           
                                                             ≥60: 34.8%                                                                                                                                                                                                                                

  Pan et al,[@b17-dddt-11-851] 2013     206                  50.03                                            1\. HCC without previous treatment\                                                                         Surgery alone                  (adjusted) 0.495\      NR                     NR
                                                                                                              2. Child--Pugh class A or no Cirrhosis                                                                                                     (0.699--0.35)                                 

                                        204                  49.16                                            3\. Solitary HCC\                                                                                           Surgery + CIK                                                                
                                                                                                              4. Adequate liver functional reserve to survive the operation                                                                                                                            

  Huang et al,[@b16-dddt-11-851] 2013   85\                  50[a](#tfn3-dddt-11-851){ref-type="table-fn"}\   1\. Diagnosis meeting the AASLD and the EASL criteria for HCC\                                              TACE + RFA + CIK\              0.56 (0.40--0.77)      0.67 (0.53--0.85)      NR
                                        89                   53[a](#tfn3-dddt-11-851){ref-type="table-fn"}    2. ECOG score 0 or 1\                                                                                       TACE + RFA                                                                   
                                                                                                              3. Child--Pugh class A or B, good liver function\                                                                                                                                        
                                                                                                              4. No previous surgery, chemotherapy or radiotherapy for HCC\                                                                                                                            
                                                                                                              5. No portal vein thrombosis                                                                                                                                                             

  Tong et al,[@b28-dddt-11-851] 2013    20\                  56                                               Inoperable HCC, diagnosed according to AASLD 2010                                                           TACE + CIK\                    0.4 (0.19--0.84)       0.55 (0.33--0.93)      NR
                                        18                                                                                                                                                                                TACE only                                                                    

  Deng et al,[@b24-dddt-11-851] 2013    21                   ≥50: 81.0%\                                      1\. Diagnosed according to AASLD\                                                                           TACE + RFA                     0.76 (0.51--1.11)      NR                     0.47 (0.25--0.88)
                                                             \<50: 19.0%                                      2. Normal liver function, and AFP \>25 ng/mL                                                                                                                                             

                                        20                   ≥50: 65.0%\                                      3\. Solitary HCC, tumor ≤3; no tumor thrombosis or distant metastasis\                                      TACE + RFA + CIK                                                             
                                                             \<50: 35.0%                                      4. No residual tumor after 8-weeks treatment with TACE and RFA; AFP \<37.5 ng/mL for \>2 weeks                                                                                           

  He et al,[@b25-dddt-11-851] 2012      58\                  52.1\                                            1\. Age \>18 years\                                                                                         TACE only TACE + CIK           0.52 (0.38--0.70)      NR                     NR
                                        60                   56.3                                             2. Diagnosis according to Chinese anticancer association\                                                                                                                                
                                                                                                              professional committee of liver cancer                                                                                                                                                   

  Wang et al,[@b30-dddt-11-851] 2012    38                   53                                               1\. Diagnosed primary HCC according to AASLD\                                                               TACE + RFA + CIK               (adjusted) 0.830\      NR                     0.579 (0.381--0.880)
                                                                                                              2. Tumor diameter \>3 cm; tumor diameter ≤3 cm combined\                                                                                   (0.551--1.250)                                
                                                                                                              portal vein hypertension; or hyperbilirubinemia                                                                                                                                          

                                        38                   55                                               3\. Multiple tumors\                                                                                        TACE + RFA                                                                   
                                                                                                              4. ECOG score \>1\                                                                                                                                                                       
                                                                                                              5. Child--Pugh class A or B                                                                                                                                                              

  Hao et al,[@b15-dddt-11-851] 2010     72\                  53[a](#tfn3-dddt-11-851){ref-type="table-fn"}\   1\. Age \>18 years\                                                                                         TACE + CIK TACE only           0.448 (0.244--0.822)   0.564 (0.361--0.883)   NR
                                        74                   51[a](#tfn3-dddt-11-851){ref-type="table-fn"}    2. Patients had unresectable HCC or refused resection\                                                                                                                                   
                                                                                                              3. Total bilirubin \<3× upper limit or normal\                                                                                                                                           
                                                                                                              4. Child--Pugh class A or B\                                                                                                                                                             
                                                                                                              5. No extrahepatic metastasis\                                                                                                                                                           
                                                                                                              6. Newly diagnosed or postoperative recurrence                                                                                                                                           

  Dong et al,[@b14-dddt-11-851] 2009    41                   ≥50: 65.9%\                                      1\. Solitary tumor\                                                                                         Surgery + CIK-I                0.98 (0.67--1.44)      NR                     0.67 (0.50--0.89)
                                                             \<50: 34.1%                                      2. No postoperative transfusion                                                                                                                                                          

                                        43                   ≥50: 60.5%\                                      3\. HCC confirmed by pathology\                                                                             Surgery + CIK-II                                                             
                                                             \<50: 39.5%                                      4. Resection margin \>1 cm                                                                                                                                                               

                                        43                   ≥50: 65.1%\                                      5\. No tumor fracture or hemorrhage\                                                                        Surgery only                                                                 
                                                             \<50: 34.9%                                      6. No tumor distant metastases                                                                                                                                                           

  Yu et al,[@b32-dddt-11-851] 2009      25                   49                                               Primary HCC postsurgical resection, with pathological diagnosis of HCC                                      Surgery + TACE + CIK           0.92 (0.34--2.51)      NR                     NR

                                        25                   52                                                                                                                                                           Surgery + supportive therapy                                                 

  Weng et al,[@b13-dddt-11-851] 2008    45\                  43[a](#tfn3-dddt-11-851){ref-type="table-fn"}\   1\. Histologically and clinically confirmed nodular or massive HCC\                                         TACE + RFA + CIK TACE + RFA    NR                     NR                     0.59 (0.28--1.27)
                                        40                   45[a](#tfn3-dddt-11-851){ref-type="table-fn"}    2. Tumor diameters ranged from 2 to 13 cm\                                                                                                                                               
                                                                                                              3. No tumor embolus in portal vein or remote metastasis\                                                                                                                                 
                                                                                                              4. Child--Pugh class A or B KPS \>90                                                                                                                                                     

  Huang et al,[@b26-dddt-11-851] 2007   55\                  46.2\                                            1\. Histologically and clinically confirmed nodular or massive HCC\                                         TACE + RFA + CIK TACE + RFA    0.36 (0.15--0.89)      NR                     NR
                                        30                   47.1                                             2. Patients had TACE + RFA for 2--3 times, without residual\                                                                                                                             
                                                                                                              tumor or distant metastasis                                                                                                                                                              

  Shi et al,[@b31-dddt-11-851] 2007     38\                  NR                                               Primary HCC                                                                                                 TACE + CIK TACE                0.21 (0.10--0.44)      NR                     NR
                                        134                                                                                                                                                                                                                                                            

  Hao et al,[@b29-dddt-11-851] 2006     21\                  50.90\                                           Patients diagnosed HCC according to Chinese anticancer association professional committee of liver cancer   TACE + CIK TACE only           0.6 (0.3--1.2)         NR                     NR
                                        46                   49.83                                                                                                                                                                                                                                     

  Zhang et al,[@b27-dddt-11-851] 2006   30\                  45.5                                             Primary HCC                                                                                                 TACE only\                     0.7 (0.53--0.93)       NR                     NR
                                        16\                                                                                                                                                                               TACE + CIK\                                                                  
                                        36                                                                                                                                                                                TACE + PEI + CIK                                                             
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Median age was presented.

**Abbreviations:** AASLD, American Association for the study of liver diseases; AFP, α-fetoprotein; AJCC, American Joint Committee on Cancer; BCLC, Barcelona Clinic Liver Cancer; CIK, cytokine-induced killer; DFS, disease-free survival; EASL, European Association for the Study of the Liver; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; HCC, hepatocellular carcinoma; KPS, Karnofsky Performance Score; NR, not recorded; OS, overall survival; PEI, percutaneous ethanol injection; PFS, progression-free survival; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization.
